Androgen suppression therapy and prostate cancer: Balancing the harms and the benefits

Cancer

Volumn 113, Issue 12, 2008, Pages 3275-3278

  Oefelein, Michael G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SUPPRESSION THERAPY; ANTIANDROGEN THERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; EARLY INTERVENTION; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HEART DEATH; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MALE; MEMORY DISORDER; METASTASIS; MOOD DISORDER; MORBIDITY; NEUROLOGIC DISEASE; OBESITY; ORCHIECTOMY; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; QT PROLONGATION; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME; WATCHFUL WAITING; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEER PROGRAM;

EID: 57649114172     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23971     Document Type: Editorial

References (22)

1. Shahininan VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
2. Almeida OP, Waterreus A, Spry N, Flicker L, Martin RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29:1071-1081.
3. Keating NJ, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456.
4. Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol. 2003;169:251-255.
5. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599-603.
6. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979-3983.
7. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305-1308.
8. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34:2-11.
9. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165-170.
10. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K;Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004;172(5 pt 1):1865-1870.
11. Byar DP. The veterans Administration Cooperative Urological Research Group's study of cancer of the prostate. Cancer. 1973;32:1126-1130.
12. Kent JR, Bischoff AJ, Arduino LJ. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol. 1973;109:858-860.
13. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goseralin. N Engl J Med. 1997;337:295-300.
14. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer, a randomized trial. JAMA. 2008;299:289-295.
15. Messing EM, Manola J, Yao J, et al.; Eastern Cooperative Oncology Group study. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472-479.
16. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-591.
17. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008;113:3290-3297.
18. Prandoni P, Lensing AWA, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
19. Oefelein MG, Brant M, Crotty K. Idiopathic thromboembolism as the presenting sign of occult prostate cancer. Urology. 1998;51:775-780.
20. Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316-1318.
21. Duggirala MK, Cook DA, Mauck KF, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;349:401-402.
22. Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005;26:3-4.